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Acquired potential N-glycosylation sites within
the tumor-specific immunoglobulin heavy chains
of B-cell malignancies
Recent reports have shown that humanB-cell malignancies are characterizedby an extremely variable incidence of
acquired, potential N-glycosylation sites
(AGS) in their tumor-specific immunoglob-
ulin (Ig) variable region sequences.1-2 In par-
ticular, most3 if not all4 cases of follicular
lymphoma (FL) present with this feature,
whereas other B-cell malignancies, includ-
ing those that, like FL, originate from the
germinal center, show a substantially low-
er occurrence of this phenomenon.1-2 This
molecular difference is unlikely to be sole-
ly of a stochastic nature, but so far no
explanation has been provided for it.  Fur-
thermore, it is unclear whether the pres-
ence of AGS has prognostic and/or thera-
peutic implications. Here, we describe our
findings on the of incidence and peculiar
presentation patterns of these AGS in first-
relapse B-cell malignancies including, for




We retrospectively analyzed all forty-sev-
en consecutive B-cell malignancy cases
considered as potential candidates to
receive the idiotype (Id) vaccine currently
under investigation at our institution.5
Since the respective clinical trials only
required sequencing of the Ig heavy chain
variable region (VH) fragments including
both complementarity-determining regions
(CDR) 2 and 3,6 it is possible that those cas-
es with AGS in other regions of the Ig mol-
ecule may have been judged as false neg-
atives. All patients described here were in
first relapse and their diagnosis was deter-
Background and Objectives. Among B-cell malignancies, follicular lymphomas (FL)
more frequently show acquired, potential N-glycosylation sites (AGS) within tumor-spe-
cific immunoglobulin. The aim of this study was to extend this observation and to eval-
uate the pattern of presentation of AGS within five different forms of B-cell lymphoma. 
Design and Methods. We sequenced the tumor-specific immunoglobulin heavy chain
variable region fragment, including complementarity-determining regions 2 and 3, of
forty-seven consecutive patients with a B-cell malignancy enrolled in idiotype vaccine
clinical trials. This sequencing approach is known to allow the identification of most AGS.
We then statistically analyzed differences in presentation pattern, in terms of tumor his-
tology, immunoglobulin isotype, AGS location and amino acid composition.
Results. All twenty-four FL cases presented with at least one AGS, whereas the vast
majority of four B-cell lymphoma types other than FL did not. The non- FL group of tumors
included four cases of Burkitt’s lymphoma, six of diffuse large cell lymphoma, seven man-
tle cell lymphomas and six small lymphocytic lymphomas. Most IgM-bearing follicular
lymphoma cases featured their AGS within complementarity-determining region 2, as
opposed to those bearing an IgG, which mostly displayed the AGS within complementar-
ity-determining region 3. The vast majority of AGS located within either complementar-
ity-determining region ended with a serine residue, whereas those located within frame-
work regions mostly featured threonine as the last amino acid residue.   
Interpretation and Conclusions. In our series, all cases of FL had AGS within their
tumor-specific immunoglobulin heavy chain variable regions. In contrast, most B-cell
malignancies other than FL did not. Further studies are warranted in order to establish
the possible meaning of these findings in terms of disease pathogenesis, their diagnostic
value in doubtful cases and their potential implications for immunotherapy. 
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mined independently without knowledge of the pres-
ence or absence of AGS.
Identification of the surface tumor-specific Ig
isotype
Fresh tumor cells were washed twice in phosphate-
buffered saline (PBS), resuspended and incubated for
15 minutes at room temperature with goat anti-
human IgM-FITC, goat anti-human IgG-FITC and goat
anti-human IgA-FITC (Biosource International, Camar-
illo, CA, USA). Finally, following a further wash in PBS,
flow cytometry analysis was carried out in a FACScan
(BD Immunocytometry System, Mountain View, CA,
USA) using the CellQuest software.
Sequencing of VH CDR2 and CDR3
All methodological details concerning the identifi-
cation process of the VH CDR2 and CDR3 sequences on
which this study is based have been previously pub-
lished.8-9
Briefly, following total RNA extraction and first
cDNA synthesis, polymerase chain reaction (PCR)
amplifications were performed using both consensus
primers7 and the PCR conditions7-8 previously described.
PCR products were subsequently purified using the
Qiaquick PCR purification kit (Qiagen, Hilden, Ger-
many), according to the manufacturer's instructions.
Cycle sequencing was carried out using the BigDye
terminator kit (Applied Biosystems, Foster City, CA,
USA), and a 377 ABI-PRISM sequencer (Applied
Biosystems) was used for the automated sequencing.
All PCR product-related electropherograms were
aligned to the closest germ line counterpart9 using the
Sequence Navigator software (Applied Biosystems) and
the final sequence analyses were performed utilizing
the IgBLAST program at the NCBI web site
(http://www.ncbi.nlm.nih.gov/igblast).
Statistical analysis
Fisher's exact test was used for all group compar-
isons: a 2-tail p < 0.05 was considered statistically sig-
nificant.
Results
Acquired, potential N-glycosylation sites were found
in all 24 (100%) FL cases, but in only 2/23 (9%) cases
of B-cell malignancy other than FL. Among the 23
non-FL cases, six cases had no somatic mutations and
were, thus, unlikely to have AGS. Therefore, the inci-
dence of AGS among non-FL B-cell malignancies in
which some somatic mutations had occurred was 2/17
(12%; p<0.0005) (Table 1). Within the FL cases, histo-
logic grade10,11 did not influence the number of AGS
(Table 1). Furthermore, in six of the FL cases, tumor-
specific Igs involved a germ line gene with a natural,
potential N-glycosylation site (NGS): V4-34 in all cas-
es. However, in all six cases, the NGS was lost and at
least one novel AGS had been acquired (Figure 1).
All six cases of primary diffuse large B-cell lym-
phoma (DLCL) were characterized by a completely dif-
ferent pattern. In no case did the tumor-specific Ig
derive from a germ line bearing an NGS (Figure 2) or
develop any AGS, despite containing somatic muta-
tions (Figure 2). Moreover, the germ line genes from
which DCLC tumor-specific Igs were derived curious-
ly always differed from those related to FL-specific Igs
(Figure 1 and 2).
Regarding MCL, it is known that, although the vast
majority of tumor-specific Igs do not have somatic
mutations, a limited number of such Igs may have
somatic mutations as a consequence of being of fol-
licular or post-follicular origin.12-14 Among our seven
cases of MCL, four had no mutations (Figure 2), includ-
ing one case (MCL5, which only showed one possible
mutation involving the last amino acid before the N-
terminus of CDR3) derived from V4-34 and, as such,
bearing one NGS. On the other hand, 1 of 3 cases of
somatically mutated MCL had an AGS (Figure 2).
Among our six cases of SLL, four were characterized by
a tumor-specific Ig featuring at least a few somatic
mutations. However, none of them had an AGS (Fig-
ure 2).
Finally, only one of our four cases of sporadic
Burkitt's lymphoma (BL) had an AGS despite the pres-
ence of somatic mutations in all four cases (Figure 2).
All thirty-seven AGS detected in our study were ana-
lyzed for possible occurrence within a hotspot for
somatic mutations according to the definition of the
RGYW motif.15 Only one out of four AGS located with-
in a framework region (FR) presented this feature. In
contrast, AGS located in any CDR occurred within such
a hotspot in 8/16 (50%) and in 7/9 (77%) cases, respec-
tively, depending on whether or not the AGS present in
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Table 1. Frequency of acquired, potential N-glycosylation
sites (AGS) within the VH FR2-CDR3 sequence fragment
of B-cell tumor-specific Igs.
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Figure 1. Location of AGS within the VH FR2-CDR3 sequence fragment of B-cell tumor-specific Igs. Dots represent iden-
tity with the corresponding germ line sequence, whereas the novel sites are highlighted. Boxes indicate AGS occur-
ring within somatic mutation hotspots according to the definition of the RGYW motif.
Figure 2. VH FR2-CDR3 sequence fragments belonging to B-cell tumor-specific Igs not presenting AGS. Dots repre-
sent identity with the corresponding germ line sequence.
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sequences derived from the NGS-bearing V4-34 germ
line gene were taken into account (Figure 1).
The location of somatic mutation-induced AGS is
different in IgM and IgG (Figure 3). In particular, 7/9
AGS-containing, IgM-bearing FL displayed an AGS at
or near the N-terminus of the CDR2, whereas the
remaining cases (2/9) featured the AGS near or at the
N-terminus of the CDR3. In contrast, 10/14 AGS-con-
taining, IgG-bearing FL displayed an AGS at or near the
N-terminus of the CDR3, whereas 4/14 featured the
AGS at or near the N-terminus of the CDR2. However,
the location of the AGS correlated only with isotype.
Two IgG-expressing cases had AGS in both CDR2 and
CDR3 (FL2, FL24) and in one of these cases (FL24), nei-
ther AGS was near the N-terminus of the region. All
in all, the likelihood of finding an AGS at or near the
N-terminus of the CDR2 was markedly higher in clon-
al IgM-bearing FL (p=0.036), whereas the likelihood of
finding an acquired site at or near the N-terminus of
the CDR3 was significantly higher in clonal IgG-bear-
ing FL (p=0.036). Moreover, none of the twenty-four
FL cases had an AGS only outside the CDR2 and the
CDR3 in contrast to the non-FL cases, in which the
only identified AGS was found in both cases within
the FR 3 (p=0.003) (Figure 3). Finally, among B-cell
malignancies bearing no AGS, the presence of a
tumor-specific Ig of IgM isotype was demonstrated in
most BL, MCL and SLL cases, whereas the same trend
did not emerge among DLCL cases (Figure 4).
The amino acid sequences of individual AGS differed
when the site was in a CDR rather than a FR (Figure
3). Eighty-six percent (25/29) of AGS located within
any CDR ended with serine, whereas 3/4 of the AGS
found within FR3, had threonine as the last amino acid
(p=0.023).
Discussion
Acquired, potential N-glycosylation sites are a fea-
ture of the immunoglobulin genes on the surface of
follicular lymphoma cells that have undergone somat-
ic mutation. With this study, we extend and confirm
prior reports on this phenomenon,1,2 show a correlation
between the location of the AGS and the FL Ig isotype,
identify amino acid sequence differences between AGS
in CDR versus FR, and assess the frequency of AGS in
other B-cell tumors.
An obvious limitation of our data on the acquisition
of AGS by the tumor-specific Igs of first-relapse B-
cell malignancies is that they are still numerically very
limited. Moreover, although it appears ever more evi-
dent that the vast majority of acquired sites lie with-
in VH CDR2 and CDR3,1-2 some AGS do not. Therefore,
since our data refer only to these two CDRs, a com-
prehensive assessment of AGS has not yet been per-
formed. 
On the other hand, a few features are becoming
clear. For instance, AGS may be useful to distinguish
authentic FL from other types of lymphoma. In our
series, 2 cases originally classified as FL were found to
lack AGS and central review found that the diagnosis
in both cases was SLL. Of course, this is not sufficient
to consider the presence of AGS as an element capa-
Figure 3. Distribution of AGS within the VH FR2-CDR3 sequence fragments according to histology and Ig isotype.
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ble of defining cases of FL.1 However, the analyses of
samples from larger groups of patients might help to
determine whether AGS could become a defining fea-
ture of FL.
It is striking that no AGS were detected within the
mutated sequences of DLCL cases. Many FL under his-
tologic progression to DLCL and a substantial fraction
of de novo DLCL cases are thought to be derived from
follicular center cells.16 It will be important to compare
AGS in de novo DLCL and in DLCL that has progressed
from FL to see whether the processes by which these
diseases develop are similar or different.
It is also interesting that the acquisition of AGS
occurs in different places as a function of Ig isotype:
preferentially within CDR2 for IgM and within CDR3 for
IgG. Even when the tumor Ig contains an NGS (V4-34
germ line) in the CDR2 (Figure 1), IgM-expressing FL
lose the NGS and acquire an AGS in the CDR2, where-
as an IgG-expressing FL (FL20), lost the CDR2 NGS and
acquired an AGS within CDR3. These data argue that
the AGS location is affected by the Ig isotype.
The role of AGS is undefined, but it may be both of
value to enhance antigen binding and exploitable in
our clinical efforts to make a selective and specific
tumor vaccine. Asn, Trp, Tyr and Ser, but not Thr, are
amino acids within the combining sites known to
improve the affinity of antibody for antigen.17-18 Simi-
larly, an Ig with these somatic mutations may be more
strongly antigenic when used as a vaccine rather than
as an antibody.19-20 In this respect, the presence of AGS,
particularly in FL-specific Igs, might per se enhance
both the specificity and the efficacy of any vaccine-
induced, Id-specific, polyclonal, humoral response, pos-
sibly targeting these portions of the Id-containing Ig
amino acid sequence. Whether similar considerations
may also apply more broadly to vaccine-induced, Id-
specific, T-cell responses remains speculative, as the
exact location and distribution of the single idiotopes
within the Ig variable regions has yet to be  elucidat-
ed.
The role of AGS in the immunogenicity of tumor
immunoglobulin has not yet been defined. Structural
studies are needed to assess whether these sites are
actually glycosylated in tumor cells or are merely
potential sites for glycosylation. In addition, this vari-
able may need to be examined in the framework of
idiotype rescue in the generation of idiotype vaccines.
If important idiotopes were glycosylated on the tumor-
specific immunoglobulin, it would be reasonable to
suggest that the immunogen used to elicit an immune
response to the tumor should also be glycosylated. To
date, the influence of this variable on the outcome of
idiotypic vaccination has not been assessed. It may be
necessary to undertake comparisons of glycosylated
and non-glycosylated idiotype vaccines to assess
whether the AGS may enhance the effectiveness of
idiotype-directed therapies.
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Figure 4. Distribution of VH FR2-CDR3 sequence fragments not bearing AGS according to histology and Ig isotype. 
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